Mortality among British Columbians testing for hepatitis C antibody

BMC Public Health

Volumn 13, Issue 1, 2013, Pages

  Yu, Amanda ^a,b   Spinelli, John J ^b,c   Cook, Darrel A ^a   Buxton, Jane A ^a,b   Krajden, Mel ^a,b  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Chronic hepatitis; Data linkage; Hepatitis C virus; Injection drug use; Mortality

Indexed keywords

HEPATITIS C ANTIBODY;

ADDICTION; ADULT; ARTICLE; BLOOD; CANADA; CAUSE OF DEATH; FACTUAL DATABASE; FEMALE; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; LIVER DISEASE; MALE; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; VIROLOGY;

ADULT; BRITISH COLUMBIA; CAUSE OF DEATH; DATABASES, FACTUAL; FEMALE; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK-TAKING; SUBSTANCE-RELATED DISORDERS;

MLCS; MLOWN;

EID: 84875481317     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-13-291     Document Type: Article

References (39)

1. Remis RS, Modelling the incidence and prevalence of hepatitis C infection and its sequelae in Canada, 2007 Health Canada, Ottawa: Final report 2007 [ http://www.phac-aspc.gc.ca/sti-its-surv-epi/model/pdf/model07-eng.pdf ]
2. Public Health Agency of Canada, Hepatitis C [ http://www.phac-aspc.gc.ca/ hepc/index-eng.php ]
3. Prediction of hepatitis C burden in Canada. Zou S, Tepper M, El Saadany S, Can J Gastroenterol 2000 14 575 580 10978943
4. Course and outcome of hepatitis C. Hoofnagle JH, Hepatology 2002 36 Suppl 1 21 S29 12407573
5. Natural history of chronic hepatitis C. Seeff L, Hepatology 2002 36 Suppl 1 35 S46 12407575
6. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Thein H-H, Yi Q, Dore GJ, Krahn MD, Hepatology 2008 48 418 431 10.1002/hep.22375 18563841
7. Centers for Disease Control Prevention, Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-related Chronic Disease US Dept. of Health and Human Services, Centers for Disease Control and Prevention 1998 [ http://www.cdc.gov/mmwr/preview/mmwrhtml/00055154.htm ]
8. Scope of worldwide hepatitis C problem. Brown RS, Gaglio PJ, Liver Transpl 2003 9 Suppl 3 10 S13 14586889
9. Understanding Hepatitis C. McHutchison JG, Am J Manag Care 2004 10 Suppl 2 21 S29 15084064
10. Global challenges in liver disease. Williams R, Hepatology 2006 44 521 526 10.1002/hep.21347 16941687
11. Management of hepatitis C infected liver transplant recipients at large North American centres: changes in recent years. Khalili M, Vardanian AJ, Hamerski CM, Wang R, Bacchetti P, Roberts JP, Terrault NA, Clinical Transplant 2006 20 1 9
12. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ, Lancet 2006 368 938 945 10.1016/S0140-6736(06)69374-4 16962883
13. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community based register study. Duberg AS, Törner A, Daviisdóttir L, Aleman S, Blaxhult A, Svensson Å Hultcrantz R, Bäck E, Ekdahl K, J Viral Hepat 2008 15 538 550 10.1111/j.1365-2893.2008. 00982.x 18397223
14. Total and cause specific mortality rates in a prospective study of community acquired hepatitis C virus infection in northern Norway. Kristiansen MG, Løchen ML, Gutteberg TJ, Mortensen L, Eriksen BO, Florholmen J, J Viral Hepat 2010 18 237 244
15. A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. McDonald SA, Donaghy M, Goldberg DJ, Hutchinson S, Robertson C, Bird S, Mills P, Dillon J, Bloor M, Hayes P, Graham L, Stat Methods Med Res 2009 18 271 10.1177/0962280208094690 19036907
16. Impact of a sustained virological response on the long-term outcome of hepatitis C. Alberti A, Liver Int 2011 31 18 22 21651701
17. A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA, Clin Gastroenterol Hepatol 2011 9 509 516 10.1016/j.cgh.2011.03.004 21397729
18. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Pawlotsky J-M, Hepatology 2011 53 1742 1751 10.1002/hep.24262 21374691
19. A Method to Visualize and Adjust for Selection Bias in Prevalent Cohort Studies. Törner A, Dickman P, Duberg A-S, Kristinsson S, Landgren O, Bjorkholm M, Svensson A, Am J Epidemiol 2011 174 969 976 10.1093/aje/kwr211 21920949
20. A Proposed Method to Adjust for Selection Bias in Cohort Studies. Törner A, Duberg A-S, Dickman P, Svensson à Am J Epidemiol 2010 171 602 608 10.1093/aje/kwp432 20106936
21. Healthcare Costs Associated with Hepatitis C: A Longitudinal Cohort Study. Krajden M, Kuo M, Zagorski B, Alvarez M, Yu A, Krahn M, Can J Gastroenterol 2010 24 717 726 21165379
22. Population Data BC, [ http://www.popdata.bc.ca/ ]
23. Breslow NE, Day NE, Statistical methods in cancer research Volume II-The design and analysis of cohort studies. Lyon, France; International Agency for Research on Cancer: Volume II-The design and analysis of cohort studies 1987
24. Time-dependent covariates in the Cox proportional-hazards regression model. Fisher LD, Lin DY, Ann Rev Public Health 1999 20 145 157 10.1146/annurev.publhealth.20.1.145
25. Stryhn H, Christensen J, Confidence intervals by the profile likelihood method, with applications in veterinary epidemiology. In Proceedings of the 10th International Symposium on Veterinary Epidemiology and Economics, Vina del Mar Chile. International Symposia on Veterinary Epidemiology and Economics 2003
26. Therneau T, Grambsch P, Modeling Survival Data New York; Springer-Verlag: Extending the Cox Model (Statistics for Biology and Health) 2000
27. No Impact of Hepatitis C Virus Infection on Mortality Among Drug Users During the First Decade After Seroconversion. Grady B, van Den Berg C, van der Helm J, Schinkel J, Coutinho R, Krol A, Prins M, Clin Gastroenterol Hepatol 2011 9 786 792 10.1016/j.cgh.2011.05.012 21699803
28. Clinical course of hepatitis C virus during the first decade of infection: cohort study. Harris HE, Ramsay ME, Andrews N, Eldridge KP, Br Med J 2002 324 450 10.1136/bmj.324.7335.450
29. Incidence and Transmission Patterns of Acute Hepatitis C in the United States, 1982-2006. Williams IT, Bell BP, Kuhnert W, Alter MJ, Arch Intern Med 2011 171 242 248 10.1001/archinternmed.2010.511 21325115
30. Mortality in patients with chronic and cleared hepatitis C viral infection: A nationwide cohort study. Omland LH, Krarup H, Jepsen P, Georgsen J, Harritshøj LH, Riisom K, Jacobsen SEH, Schouenborg P, Christensen PB, Sørensen HT, J Hepatol 2010 53 36 42 10.1016/j.jhep.2010.01.033 20400197
31. McGuinness LK, Enhanced Hepatitis Strain and Surveillance System (EHSSS) in Review 2009 [ http://www.bccdc.ca/NR/rdonlyres/B5416770-25AF-4FAB-A392- F7CCA7471635/0/EHSSSBCCDCSiteReport200009Feb2010.ppt#256,1,Enhanced Hepatitis Strain & Surveillance System (EHSSS) in Review]
32. All-Cause, Liver-Related, and Non-Liver-Related Mortality Among HCV-Infected Individuals in the General US Population. El-Kamary SS, Jhaveri R, Shardell MD, Clin Infect Dis 2011 53 150 157 10.1093/cid/cir306 21665867
33. HIV/AIDS in Vancouver, British Columbia: a growing epidemic. McInnes CW, Druyts E, Harvard SS, Gilbert M, Tyndall MW, Lima VD, Wood E, Montaner JSG, Hogg RS, Harm Reduction J 2009 6 1 5 10.1186/1477-7517-6-1
34. Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting. Kim C, Kerr T, Li K, Zhang R, Tyndall M, Montaner J, Wood E, BMC Public Health 2009 9 270 10.1186/1471-2458-9-270 19640297
35. HCV co-infection in HIV positive population in British Columbia, Canada. Buxton JA, Yu A, Kim PH, Spinelli JJ, Kuo M, Alvarez M, Gilbert M, Krajden M, BMC Public Health 2010 10 225 10.1186/1471-2458-10-225 20429917
36. BC Centre for Disease Control, Harm Reduction [ http://www.bccdc.ca/ prevention/HarmReduction/default.htm ]
37. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M, Hepatology 2012 55 49 57 10.1002/hep.24656 21898506
38. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C, the HEPATIS Group, J Viral Hepat 2001 8 87 95 10.1046/j.1365-2893.2001.00280.x 11264728
39. Statistics Canada, Deaths 2009 [ http://www.statcan.gc.ca/pub/84f0211x/ 84f0211x2009000-eng.pdf ]